CO-TECHSTARS
20.4.2022 14:02:25 CEST | Business Wire | Press release
Techstars, a global investment business that provides access to capital, one-on-one mentorship, and customized programming for early-stage entrepreneurs, announces two strategic and operational leaders who will join the global management team effective immediately. Aparna Ramaswamy will serve as the new Chief Human Capital Officer and Kimberly Smith has been appointed to the newly formed role as Chief Capital Formation Officer, both positions report to CEO, Maëlle Gavet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220420005309/en/
“The best capital - whether human or financial - will pave the way for Techstars in its ambition to become the largest pre-seed investor," said Gavet. "These two deeply talented and experienced operational leaders will help Techstars continue its growth worldwide for our proven and scalable investment business."
As the new Chief Human Capital Officer, Ramaswamy has experience across a diverse portfolio of global businesses and industries/sectors including financial services, oil and gas, security, aviation, and public education. She has a recognized track record of shaping change through a strategic approach of aligning people and culture to enable businesses to scale and solve complex problems. In her most recent role as Chief Human Capital Officer for Success Academy Charter Schools in New York City, she introduced an innovative two-year leadership fellows program (Robertson Leadership Fellows) to accelerate and build the school leadership pipeline at scale and also created and led the first Inclusion Council and DEI commitments for a network of 47 public charter schools serving 20,000 children across four NYC boroughs. With Techstars’ recent announcement , launching nine diverse-led accelerators programs in partnership with J.P. Morgan, Ramaswamy’s experience in building and leading DE&I related initiatives at scale will be invaluable to the organization.
Prior to her most recent leadership role with Success Academy Charter Schools, Ramaswamy served as Co-Head of Human Resources at Bridgewater Associates and before that, spent 14 years at General Electric (GE) in progressively larger global Human Resources leadership roles across multiple businesses and industries. Based in Stamford, Connecticut, she plans to bring to Techstars her broad and varied range of global experience in talent acquisition, leadership capacity building, talent management, and total rewards, to reinforce operational excellence and deliver on Techstars’ key strategic objectives.
Ramaswamy received a Bachelor of Arts in Sociology and Psychology from St. Xavier’s College in Mumbai, India, a Master of Arts in Sociology from the University of Mumbai, India, and a Master of Business Administration from the University of Michigan Ross School of Business. In her free time, she serves on the American India Foundation Tri-State Board and is a member of the Vitalize VC Angels investment community, and the Chief Network.
Named as Techstars’ first Chief Capital Formation Officer, Smith joined the company in September 2021 and immediately began making an impact through her influence with prospective and existing investors and Limited Partners (LPs). She was integral in helping the organization close the Advancing Cities fund last month.
Based in New York City, she will be responsible for Tecshstars’ fundraising and investor relations while cultivating relationships with current and future investors - both traditional institutional LPs as well as individuals and strategic investors. Smith has spent her career raising money in the investment management sector and before joining Techstars, spent 15+ years with Owl Creek Asset Management, a NY-based event driven hedge fund, where she was a Partner and responsible for raising and retaining billions of investor capital. She has also held leadership positions in Investor Relations and Marketing at Davidson Kempner, traded coffee and sugar in the Global Futures group at ABN AMRO and got her start in finance working at Ziff Brothers.
Smith received her Bachelor of Arts from Middlebury College and her Masters of Business Administration from Fordham University. She is also the Chair of both the Board of Trustees and the Investment Committee at the Ethical Culture Fieldston School in New York City.
Following four other executive appointments within the last year, Techstars is taking bold and ambitious steps toward bringing together an industry team of leaders focused on building and growing a world-class investment business at scale.
About Techstars
The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas—entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 3,000 companies with a combined market cap of more than $172B. www.techstars.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005309/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
